基因与颅咽管瘤复发.pdf

J Neurooncol (2007) 83:183–189 DOI 10.1007/s11060-006-9284-0 CLINICAL STUDY–PATIENT STUDIES Expression of Human MCM6 and DNA Topo II a in craniopharyngiomas and its correlation with recurrence of the tumor Jianguo Xu Æ Sizhong Zhang Æ Chao You Æ Siqing Huang Æ Bowen Cai Æ Xiaojie Wang Received: 22 August 2006 / Accepted: 19 October 2006 / Published online: 5 April 2007 Springer Science+Business Media B.V. 2007 Abstract Craniopharyngioma often recurs after resec- tumors of both subtypes the LIs of tumors with recurrence tion resulting in poor outcome for the affected patients. were higher than those without recurrence. There was a The reliable criteria for predicting the tumor behavior are strong linear positive correlation between MCM6 LI and still lacking. It has been suggested that proliferative DNA Topo II a LI (r = 0.713; p = 0.000) in the cranio- potential of the tumor cells is necessary for recurrence. pharyngiomas studied. The median MCM6 LI of the total Present study evaluated the cell multiplication activity, 20 recurrent craniopharyngiomas (31.49%) was not sig- which is possibly related to relapse in 32 patients with nificantly different from that of their primary tumors adamantine epithelioma (AE) and 31 patients with squa- (29.65%). The long term risk of tumor recurrence is mous papillary tumor (SP). For this tissue specimens from higher in AE than SP and it is associated with MCM6 and their primary and recurring tumors were collected and DNA Topo II a expression. immunohistochemical analysis of the expression of minichromosome maintenance protein 6 (MCM6) and Keywords Craniopharyngioma DNA topoisomerase II DNA topoisomerase II alpha (DNA Topo II a) in the alph